Curriculum vitae Malcolm Boyce Managing and Clinical Director ...

109 Boyce MJ, Baisley KJ, Warrington SJ. Phannacokinetic interaction between
domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a
randomized, placebo-controlled, double-blind, crossover study.
Br J Clin Phannacol2012; 73: 411-421.
110 Boyce M, Walther M, Nentwich H, Kirk J, Smith S, Warrington S. TOPS: an intemet­
based system to prevent healthy subjects from over-volunteering for clinical trials.
Eur J Clin Phannacol2012; 68: 1019-1024.
111 Boyce M, David 0, Darwin K, Mitchell T, Johnson A, Warrington S. Single oral doses
ofnetazepide (YF 4 7 6), a gastrin receptor antagonist, cause dose dependent, sustained
increases in gastric pH compared with placebo and ranitidine in healthy subjects.
Aliment Phannacol Ther 2012; 36: 181-189.
112 Oliver A, Quinn D, Goldfrad C, van Hecke B, Ayer J, Boyce M. Combined fluticasone
furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after
dosing in adult asthma: a randomised clinical trial. Clin Transl Allergy 2012.
[e-pub ahead ofprint]
113 Kent S, Boyce M, Diamant Z, Singh D, O'Connor B, Saggu P, Norris V.
The 5-lipoxygenase activating protein inhibitor, GSK2190915, attenuates the early and
late responses to inhaled allergen in mild asthma. Clin Exp Allergy 2012.
(in preparation)
114 Boyce M, Warrington S. Effect of repeated doses ofnetazepide (YF476), a gastrin
receptor antagonist, compared with placebo and omeprazole on 24-hour gastric acidity
and plasma gastrin in healthy subjects. (in preparation)
115 Boyce M, Warrington S, Black JW. Netazepide (YF476), an orally-active gastrin
receptor antagonist, causes dose-dependent, persistent inhibition of pentagastrin­
stimulated gastric acid production in healthy subjects. (in preparation)
116 Boyce M, Dowen S, Warrington, Zhao C-M, Chen D, Black JW. Netazepide (YF476),
an orally active gastrin antagonist, supresses gastric acid secretion and prevents the
increase in ECL-cell activity and rebound hyperacidity secondary to the
hypergastrinaemia induced by a proton pump inhibitor in healthy subjects.
(in preparation)
CVIMJB/28Jun2012 Page 18 of21